TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22613230

Group type: EXPERIMENTAL
Intervention: Fluid reasoning task (fMRI data collected)
Number of subjects: 22
Study: 20676928

Group type: EXPERIMENTAL
Intervention: Peer navigator intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Usual care control arm
Number of subjects: 176
Study: 17389338

Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m2/d for 5 days IV, repeated every 28 days)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Fludarabine plus cyclophosphamide (FC) (fludarabine 30 mg/m2/d for 3 days IV plus cyclophosphamide 250 mg/m2/d for 3 days, repeated every 28 days)
Number of subjects: 375
Study: 16344188

Group type: EXPERIMENTAL
Intervention: Sutter implant replacement arthroplasty
Number of subjects: 45

Group type: COMPARATOR
Intervention: Swanson implant replacement arthroplasty
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (Sutter and Swanson)
Number of subjects: 45
Study: 16540800

Group type: EXPERIMENTAL
Intervention: MMN (iron 12.5 mg + folic acid 150 microg + zinc 5 mg)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: FFA (iron 12.5 mg + folic acid 150 microg)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: MMN and FFA
Number of subjects: 204
Study: 11022872

Group type: COMPARATOR
Intervention: Water
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carbonated, non-caffeinated, citrus soft drink
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeinated caloric and non-caloric colas and coffee
Number of subjects: 18
Study: 8878221

Group type: EXPERIMENTAL
Intervention: Oral vitamin A (50,000 to 200,000 IU of retinyl palmitate, doses according to age; n = 89)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (n = 91)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral vitamin A (for subgroup with significant hypoxemia)
Number of subjects: 180
Study: 1512341

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and amiloride (50 + 5 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (19 +/- 1 mg/24 h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.6 mg)
Number of subjects: 22
Study: 6421013

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg three times a day for 1 week
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo three times a day for 1 week
Number of subjects: 6
Study: 29966038

Group type: EXPERIMENTAL
Intervention: Roxadustat (100 mg) under fed conditions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Roxadustat (100 mg) under fasted conditions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Roxadustat (100 mg) with SCA
Number of subjects: 16

Group type: COMPARATOR
Intervention: Roxadustat (100 mg) alone
Number of subjects: 16
Study: 30358565

Group type: EXPERIMENTAL
Intervention: Standard dose oseltamivir (SD)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Double dose oseltamivir (DD)
Number of subjects: 44
Study: 27041244

Group type: EXPERIMENTAL
Intervention: 40 mg/day rosuvastatin (R group, n=26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10 mg/day rosuvastatin plus 2 g/day of ω-3 PUFAs (R+O group, n=24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (55 normolipidaemic subjects)
Number of subjects: 50
Study: 24928218

Group type: EXPERIMENTAL
Intervention: Directly observed varenicline therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (self-administered varenicline)
Number of subjects: 100
Study: 22010847

Group type: EXPERIMENTAL
Intervention: Agaricus blazei Murrill (AbM) dry extract, 900 mg/day for 60 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 20467879

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine administered for 60 min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 60
Study: 17880478

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation programme
Number of subjects: 167

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 167
Study: 16583593

Group type: EXPERIMENTAL
Intervention: 20% benzocaine gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11834101

Group type: EXPERIMENTAL
Intervention: Resistance training program (10 weeks, 8 exercises for the entire body, no flexibility exercises)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (physically inactive women aged 62 to 73 years)
Number of subjects: 19
Study: 10402248

Group type: EXPERIMENTAL
Intervention: Neuroendocrine tumors (carcinoids)
Number of subjects: 25
Study: 8626261

Group type: EXPERIMENTAL
Intervention: Once daily dosing (6 mg/kg)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Thrice daily dosing (6 mg/kg)
Number of subjects: 113
Study: 31434765

Group type: EXPERIMENTAL
Intervention: Ion-exchange water softener installed prior to birth
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual domestic hard water supply
Number of subjects: 80
Study: 29179666

Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open liver resection
Number of subjects: 40
Study: 26921496

Group type: EXPERIMENTAL
Intervention: Shuangbai San
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 24828621

Group type: EXPERIMENTAL
Intervention: Interprofessional care team including a physician, nurse practitioner, clinical pharmacist, and students
Number of subjects: 0
Study: 22986336

Group type: EXPERIMENTAL
Intervention: 30 mg cortisol
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 19442259

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 20536
Study: 17313268

Group type: EXPERIMENTAL
Intervention: Progressive functional training program (8 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18
Study: 15353142

Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET EN) 200 mg used as a 2‐monthly injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not using any hormonal contraception)
Number of subjects: 50
Study: 11303833

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Placebo vaccination
Number of subjects: 1432
Study: 9599191

Group type: EXPERIMENTAL
Intervention: Protein supplementation, 20 g/d
Number of subjects: 82

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 82
Study: 8023348

Group type: EXPERIMENTAL
Intervention: Nimodipine 120 mg/d PO for 21 days
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 2661606

Group type: EXPERIMENTAL
Intervention: Benztropine 4 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Amantadine 200 mg/day
Number of subjects: 60
Study: 1229217

Group type: EXPERIMENTAL
Intervention: Desoximetason (0.25%)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Betamethasone‐valerate (0.1%)
Number of subjects: 44
Study: 31006864

Group type: EXPERIMENTAL
Intervention: Prosthetic suture repair technique
Number of subjects: 18

Group type: COMPARATOR
Intervention: Medial injury
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lateral injury
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bilateral injury
Number of subjects: 18
Study: 28988240

Group type: EXPERIMENTAL
Intervention: Intensive 1-year lifestyle treatment with 2 months inpatient period (short-stay group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intensive 1-year lifestyle treatment with 6 months inpatient period (long-stay group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Short-stay treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Long-stay treatment
Number of subjects: 80
Study: 25213082

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 30
Study: 24076103

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate solution applied for 30s after etching
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group restored with Adper Single Bond 2
Number of subjects: 70
Study: 21518686

Group type: EXPERIMENTAL
Intervention: RenalGuard System treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium bicarbonate plus N-acetylcysteine (NAC)
Number of subjects: 0
Study: 18356834

Group type: EXPERIMENTAL
Intervention: Standard group-based behavioral treatment
Number of subjects: 76
Study: 17112307

Group type: EXPERIMENTAL
Intervention: Intravenous droperidol
Number of subjects: 0
Study: 15153824

Group type: EXPERIMENTAL
Intervention: Firm inelastic bandages
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Elastic compression stockings
Number of subjects: 53

Group type: COMPARATOR
Intervention: Bed rest without any compression
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Compression (both bandages and stockings)
Number of subjects: 53
Study: 10765075

Group type: EXPERIMENTAL
Intervention: Color and power Doppler ultrasound
Number of subjects: 39
Study: 8618770

Group type: EXPERIMENTAL
Intervention: 0.02% (0.2 mg/ml) mitomycin C for 5 minutes
Number of subjects: 81

Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 81
Study: 1451240

Group type: EXPERIMENTAL
Intervention: Interposed abdominal compression-CPR
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 143
Study: 6398861

Group type: EXPERIMENTAL
Intervention: Halopemide (2 X 10 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Halopemide (2 X 20 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29731160

Group type: EXPERIMENTAL
Intervention: T2w intensity maps
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: ADC intensity maps
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Ktrans intensity maps
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: AUC analysis
Number of subjects: 260
Study: 26774919

Group type: EXPERIMENTAL
Intervention: Fluorescence lymphangiography with indocyanine green (ICG) (50 μl, 0.05%w/v)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External uniaxial loading (60 mmHg for 45 min)
Number of subjects: 0
Study: 23859303

Group type: EXPERIMENTAL
Intervention: amlodipine/benazepril 2.5/10 mg
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: amlodipine/benazepril 5/10 mg
Number of subjects: 341

Group type: COMPARATOR
Intervention: benazepril 10 mg
Number of subjects: 341
Study: 22776441

Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 242

Group type: COMPARATOR
Intervention: Community Practice
Number of subjects: 242
Study: 20667269

Group type: EXPERIMENTAL
Intervention: Participants who made between 5 and 12 mistakes
Number of subjects: 188
Study: 18590110

Group type: EXPERIMENTAL
Intervention: Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 60
Study: 15279353

Group type: EXPERIMENTAL
Intervention: Standard anatrophic nephrolithotomy (sANL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Modified anatrophic nephrolithotomy (mANL)
Number of subjects: 15
Study: 12241634

Group type: EXPERIMENTAL
Intervention: Partial median and ulnar nerve transfer; specific details on dosage and duration not available.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Phrenic and spinal accessary nerve transfer; specific details on dosage and duration not available.
Number of subjects: 23
Study: 9649906

Group type: EXPERIMENTAL
Intervention: 0‐Ex (flat surface)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 12‐Ex (12% steady inclination)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: p‐Ex (progressively increasing inclination)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Treadmill exercise testing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Graded exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ABI after exercise
Number of subjects: 10
Study: 8087937

Group type: EXPERIMENTAL
Intervention: ATP‐MgCl2 (0.1 mg/kg/min)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tolazoline (1 mg/kg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ATP‐MgCl2 (after surgery)
Number of subjects: 35
Study: 2503148

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (1320 to 1510 rets) after simple mastectomy
Number of subjects: 2800

Group type: COMPARATOR
Intervention: Careful observation of the axilla after simple mastectomy (control group)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (for left breast tumors)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (orthovoltage treatment)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (after five years)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (for left breast tumors with orthovoltage)
Number of subjects: 2800
Study: 361132

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy as an adjunct to surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone (control)
Number of subjects: 0
Study: 31779056

Group type: EXPERIMENTAL
Intervention: Full dose of quadrivalent influenza vaccine
Number of subjects: 124

Group type: COMPARATOR
Intervention: Half dose of trivalent influenza vaccine
Number of subjects: 124
Study: 29851024

Group type: EXPERIMENTAL
Intervention: 8 mL/kg Ringer's acetate solution before the induction of anaesthesia
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 219
Study: 26293163

Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every 2 weeks (120 Q2W)
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Tabalumab 120 mg every 4 weeks (120 Q4W)
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1124
Study: 25268295

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (severe deficiency subgroup)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Placebo (severe deficiency subgroup)
Number of subjects: 492
Study: 22961832

Group type: COMPARATOR
Intervention: Chlorthalidone (active control)
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: All agents
Number of subjects: 42418
Study: 20444778

Group type: EXPERIMENTAL
Intervention: Peer tutored problem‐based learning
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 142
Study: 18559291

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg/day
Number of subjects: 887

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 887
Study: 16024023

Group type: EXPERIMENTAL
Intervention: Moderate exercise (90-min treadmill walk)
Number of subjects: 20
Study: 12814447

Group type: EXPERIMENTAL
Intervention: Motilin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10838001

Group type: EXPERIMENTAL
Intervention: Group rehabilitation (GR) including eight sessions plus one booster session, combining information and/or cognitive-behavioral techniques with physical training and relaxation, starting approximately 4 months after diagnosis.
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Diagnosis-specific group meetings
Number of subjects: 132
Study: 8817823

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 432

Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine
Number of subjects: 432
Study: 1564540

Group type: EXPERIMENTAL
Intervention: Intra-arterial BCNU
Number of subjects: 448

Group type: COMPARATOR
Intervention: Intravenous BCNU
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Intravenous 5-fluorouracil
Number of subjects: 448
Study: 3970647

Group type: EXPERIMENTAL
Intervention: Pindolol (dosage not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automatic indirect BP monitoring
Number of subjects: 0
Study: 31199939

Group type: EXPERIMENTAL
Intervention: Hypothesis aware condition
Number of subjects: 84

Group type: COMPARATOR
Intervention: Hypothesis unaware condition
Number of subjects: 84
Study: 28994655

Group type: EXPERIMENTAL
Intervention: B‐SES (bioresorbable polymer‐based sirolimus‐eluting stent)
Number of subjects: 170

Group type: COMPARATOR
Intervention: R‐ZES (durable polymer‐based zotarolimus‐eluting stent)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: B‐SES
Number of subjects: 170

Group type: COMPARATOR
Intervention: R‐ZES
Number of subjects: 170
Study: 27843418

Group type: COMPARATOR
Intervention: CHO ingestion at 15 g/h
Number of subjects: 7

Group type: COMPARATOR
Intervention: CHO ingestion at 60 g/h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (amino-acid electrolyte)
Number of subjects: 7
Study: 24238825

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (2 g)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 100
Study: 22678318

Group type: EXPERIMENTAL
Intervention: Titanium endoclip
Number of subjects: 61

Group type: COMPARATOR
Intervention: Knot-tying (polyglactin) suture
Number of subjects: 61
Study: 20232751

Group type: EXPERIMENTAL
Intervention: Exogenous antioxidants
Number of subjects: 0
Study: 18814408

Group type: EXPERIMENTAL
Intervention: Phytotherapy (herbal medicine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16075255

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) using propofol/remifentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced minimal flow anesthesia using desflurane/remifentanil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total anesthesia costs for both groups
Number of subjects: 40
Study: 12430113

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Femoral Analgesia (PCFA) with 0.2% ropivacaine (boluses of 10 mL with a lockout time of 60 minutes)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Continuous Femoral Infusion (Inf) with 0.2% ropivacaine (10 mL/h)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: PCFA + Inf with 0.2% ropivacaine (5 mL/h plus boluses of 5 mL with a lockout time of 60 minutes)
Number of subjects: 140
Study: 10412269

Group type: EXPERIMENTAL
Intervention: P53 positive tumours
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: MDM2 positive tumours
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: P53(‐)/MDM2(+) phenotype
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both P53 and MDM2 positive tumours
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Only P53 positive tumours
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: P53 accumulation
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: MDM2 immunoreactivity
Number of subjects: 115
Study: 7479189

Group type: EXPERIMENTAL
Intervention: 1% acid red in propylene glycol
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 8% povidone-iodine in water
Number of subjects: 221
Study: 3067086

Group type: EXPERIMENTAL
Intervention: Penicillamine and vitamin E
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 29533525

Group type: EXPERIMENTAL
Intervention: Web-based antenatal care and education program
Number of subjects: 135

Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 135
Study: 28498207

Group type: EXPERIMENTAL
Intervention: 20 units of hyaluronidase
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 40 units of hyaluronidase
Number of subjects: 15

Group type: COMPARATOR
Intervention: No secondary injection
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Comparison of 20 vs 40 units of hyaluronidase
Number of subjects: 15
Study: 26775356

Group type: EXPERIMENTAL
Intervention: Combined general/epidural anesthesia
Number of subjects: 85

Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 85
Study: 23748819

Group type: EXPERIMENTAL
Intervention: megesterol acetate (MA) plus meloxicam (n = 23)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: meloxicam plus oral EPA-enriched nutritional supplement (n = 18)
Number of subjects: 62
Study: 20655544

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment with peer-enhanced adventure therapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Cognitive behavioral weight control treatment with supervised aerobic exercise
Number of subjects: 118
Study: 18209781

Group type: EXPERIMENTAL
Intervention: 5-HTP 100 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 20728977

Group type: EXPERIMENTAL
Intervention: Verum-acupuncture (Group 1, n = 47)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Non-specific acupuncture (Group 2, n = 54)
Number of subjects: 101
Study: 16236227

Group type: COMPARATOR
Intervention: Resistance training placebo (n=10)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistance trained creatine supplemented (n=10)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistance trained protein supplemented (n=11)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resistance trained creatine and protein supplemented (n=11)
Number of subjects: 42
Study: 11906645

Group type: EXPERIMENTAL
Intervention: GM-CSF-stimulated peripheral blood stem cell (PBSC) infusion with cyclosporin A (CsA) and 0.4 mg/kg prednisolone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group received azathioprine, 1 mg/kg prednisolone, and CsA
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: GM-CSF 450 microg on four consecutive days followed by leucopheresis and immediate transfusion of unmodified PBSC
Number of subjects: 44
Study: 10958254

Group type: EXPERIMENTAL
Intervention: venlafaxine
Number of subjects: 102

Group type: COMPARATOR
Intervention: clomipramine
Number of subjects: 102